{"schema_version":"secwatch.filing_event.v1","accession":"0001799191-23-000012","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.645470+00:00","generated_at":"2026-06-14T03:08:18.985364+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Oncology Institute CEO Brad Hively steps down, President Daniel Virnich promoted to CEO","bullets":["Brad Hively resigns as CEO effective June 30, 2023; will become Vice Chairman of the Board.","Daniel Virnich, current President, appointed CEO effective June 30, 2023.","Hively's resignation not due to any disagreement; severance includes salary continuation, 50% of 2023 bonus, and RSU vesting through June 2024.","Virnich joined TOI in 2020 as COO, promoted to President; previously at DaVita and TeamHealth."],"urls":{"canonical":"https://secwatch.observer/filing/0001799191-23-000012","json":"https://secwatch.observer/filing/0001799191-23-000012.json","markdown":"https://secwatch.observer/filing/0001799191-23-000012.md","text":"https://secwatch.observer/filing/0001799191-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/0001799191-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/toi-20230611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:08:18.985364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70e0d85dcf","claim":"Brad Hively was appointed as Vice Chair of the Board at Oncology Institute, Inc..","evidence_excerpt":"Additionally, the Board appointed Mr. Hively to serve as Vice Chair of the Board at the Effective Time","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/0001799191-23-000012-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"96032291f6","claim":"Brad Hively resigned as Chief Executive Officer at Oncology Institute, Inc..","evidence_excerpt":"On June 11, 2023, Brad Hively provided notice of his resignation as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”), effective June 30, 2023 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/0001799191-23-000012-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"be1ea6232e","claim":"Daniel Virnich was appointed as Chief Executive Officer at Oncology Institute, Inc..","evidence_excerpt":"Effective as of June 30, 2023, the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799191/000179919123000012/0001799191-23-000012-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}